<bill session="106" type="hr" number="477" updated="2013-07-14T18:52:47-04:00">
  <state datetime="2000-04-13">REFERRED</state>
  <status>
    <introduced datetime="2000-04-13"/>
  </status>
  <introduced datetime="2000-04-13"/>
  <titles>
    <title as="introduced" type="official">Expressing the sense of the House of Representatives regarding the disparity between identical prescription drugs sold in the United States, Canada, and Mexico.</title>
  </titles>
  <sponsor id="400525"/>
  <cosponsors/>
  <actions>
    <action state="REFERRED" datetime="2000-04-13">
      <text>Referred to the House Committee on Commerce.</text>
    </action>
    <action datetime="2000-04-24">
      <text>Referred to the Subcommittee on Health and Environment.</text>
      <committee name="House Committee on Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF04" subcommittee="Health and Environment" name="House Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Canada"/>
    <term name="Commerce"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Latin America"/>
    <term name="Mexico"/>
    <term name="Prescription pricing"/>
    <term name="Price policy"/>
  </subjects>
  <amendments/>
  <summary>4/13/2000--Introduced.
Expresses the sense of the House of Representatives that the cost disparity between identical prescription drugs sold in the United States, Canada, and Mexico should be reduced or eliminated.</summary>
</bill>
